Peter V. Danenberg

Medicine · Health Sciences

53h-index10.8kcitations192works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(46), Biochemical and Molecular Research(27), Genetic factors in colorectal cancer(25), Esophageal Cancer Research and Treatment(23), Gastric Cancer Management and Outcomes(20)

Publications191 total

Basic Research and Major Clinical Trials with Innovations for Individual Treatment of Colon- and Rectal Cancer Patients with a Multidisciplinary International Team: From Translational Research to National Guidelines
2024
Supplementary Table 1 from An <i>In vivo</i> Platform for Translational Drug Development in Pancreatic Cancer
2023Open Access
Data from An <i>In vivo</i> Platform for Translational Drug Development in Pancreatic Cancer
2023Open Access
Data from An <i>In vivo</i> Platform for Translational Drug Development in Pancreatic Cancer
2023Open Access
Supplementary Table 1 from An <i>In vivo</i> Platform for Translational Drug Development in Pancreatic Cancer
2023Open Access
Patient-centered developments in colon- and rectal cancer with a multidisciplinary international team: From translational research to national guidelines
World Journal of Gastrointestinal Surgery·2021· 4 citedOpen Access
Document Unit Tests Roxygen-Style [R package roxut version 0.4.0]
2021
Using cfRNA as a tool to evaluate clinical treatment outcomes in patients with metastatic lung cancers and other tumors
Cancer Drug Resistance·2021· 12 citedOpen Access
roxut: Document Unit Tests Roxygen-Style
2020Open Access
In-Line Documentation for R [R package roxygen2 version 7.1.1]
2020· 2 cited
Clinical verification of circulating tumor RNA (ctRNA) as novel pretreatment predictor and tool for quantitative monitoring of treatment response in metastatic colorectal cancer (mCRC): A biomarker study of the DEEPER trial.
Journal of Clinical Oncology·2019· 3 cited
RNA-based biomarker signatures in plasma as an independent predictor of outcome to chemotherapy in lung, colon, and breast cancers: Correlation of relative PD-L1 expression with immunotherapy outcomes.
Journal of Clinical Oncology·2019· 1 cited
Gene expression differences in cell-free RNA between prostate cancer patients and healthy individuals.
Journal of Clinical Oncology·2018· 1 cited
Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types
Biochemical and Biophysical Research Communications·2018· 48 citedOpen Access
Multi-parametric liquid biopsy analysis of circulating tumor cells (CTCs), cell-free DNA (cfDNA), and cell-free RNA (cfRNA) in metastatic castrate resistant prostate cancer (mCRPC).
Journal of Clinical Oncology·2018· 3 cited
Folates as adjuvants to anticancer agents: Chemical rationale and mechanism of action
Critical Reviews in Oncology/Hematology·2016· 46 citedOpen Access
Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types.
Journal of Clinical Oncology·2016· 1 cited
Efficiency of fluorodeoxyglucose positron emission tomography/computed tomography to predict prognosis in breast cancer patients received neoadjuvant chemotherapy
SpringerPlus·2015· 12 citedOpen Access
In-Source Documentation for R
2015
Standing the test of time: targeting thymidylate biosynthesis in cancer therapy
Nature Reviews Clinical Oncology·2014· 388 cited
page 1 of 10Next →

Frequent Co-authors

Kathleen D. Danenberg(33), Jan Brabender(15), Dennis Salonga(10), Ralf Metzger(10), Reginald V. Lord(9), Paul M. Schneider(9), Arnulf H. Hölscher(7), Heinz‐Josef Lenz(6), Susan Groshen(5), Sylke Schneider‐Burrus(5), Kumari Wickramasinghe(4), Tom R. DeMeester(4), Ji Min Park(4), Joseph R. Bertino(4), Charles Heidelberger(4), Daniel Vallböhmer(4), Yuusuke Uchida(4), Hidekazu Kuramochi(3), Jeffrey H. Peters(3), Henning Usadel(3)